{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T20:46:49Z","timestamp":1760906809989},"reference-count":22,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2003,12,1]],"date-time":"2003-12-01T00:00:00Z","timestamp":1070236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2003,12]]},"DOI":"10.1016\/j.ygyno.2003.08.001","type":"journal-article","created":{"date-parts":[[2003,10,17]],"date-time":"2003-10-17T17:42:29Z","timestamp":1066412549000},"page":"573-576","source":"Crossref","is-referenced-by-count":27,"title":["Phase 2 trial of single agent docetaxel in platinum and paclitaxel-refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum"],"prefix":"10.1016","volume":"91","author":[{"given":"Maurie","family":"Markman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristine","family":"Zanotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"Webster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gertrude","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Kulp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerome","family":"Belinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2003.08.001_BIB1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2003.08.001_BIB2","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/jnci\/92.9.699","article-title":"Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer","volume":"92","author":"Piccart","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2003.08.001_BIB3","first-page":"356a","article-title":"Randomized phase III study of cisplatin\/paclitaxel versus carboplatin\/paclitaxel in optimal stage III epithelial ovarian cancer","volume":"18","author":"Ozols","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.ygyno.2003.08.001_BIB4","first-page":"356a","article-title":"Cisplatin\/paclitaxel vs carboplatin\/paclitaxel in ovarian cancer","volume":"18","author":"du Bois","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.ygyno.2003.08.001_BIB5","first-page":"202a","article-title":"Preliminary results of the SCOTROC trial","volume":"20","author":"Vasey","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.ygyno.2003.08.001_BIB6","first-page":"202a","article-title":"Survival and longer-term toxicity results of the SCOTROC study","volume":"21","author":"Vasey","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.ygyno.2003.08.001_BIB7","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1634\/theoncologist.5-1-26","article-title":"Second-line treatment of ovarian cancer","volume":"5","author":"Markman","year":"2000","journal-title":"The Oncologist"},{"key":"10.1016\/j.ygyno.2003.08.001_BIB8","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/bjc.1989.132","article-title":"Response of patients in phase II studies of chemotherapy in ovarian cancer","volume":"59","author":"Blackledge","year":"1989","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ygyno.2003.08.001_BIB9","doi-asserted-by":"crossref","first-page":"273","DOI":"10.7326\/0003-4819-111-4-273","article-title":"Taxol","volume":"111","author":"McGuire","year":"1989","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ygyno.2003.08.001_BIB10","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1994.12.9.1748","article-title":"Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy","volume":"12","author":"Thigpen","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2003.08.001_BIB11","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1200\/JCO.1994.12.11.2301","article-title":"Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer","volume":"12","author":"Francis","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2003.08.001_BIB12","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/S0959-8049(97)00363-8","article-title":"Phase II trials of docetaxel (Taxotere\u00ae) in advanced ovarian cancer\u2014an updated overview","volume":"33","author":"Kaye","year":"1997","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ygyno.2003.08.001_BIB13","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/jnci\/87.9.676","article-title":"Docetaxel","volume":"87","author":"Piccart","year":"1995","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2003.08.001_BIB14","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1200\/JCO.2000.18.14.2733","article-title":"Docetaxel for patients with paclitaxel-resistant mullerian carcinoma","volume":"18","author":"Verschraegen","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2003.08.001_BIB15","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0090-8258(02)00091-4","article-title":"A phase II study of docetaxel in paclitaxel resistant ovarian and peritoneal carcinoma","volume":"88","author":"Rose","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2003.08.001_BIB16","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1200\/JCO.1998.16.10.3362","article-title":"A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer","volume":"16","author":"Valero","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2003.08.001_BIB17","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1200\/JCO.2000.18.12.2354","article-title":"Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens","volume":"18","author":"Fossella","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2003.08.001_BIB18","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1006\/gyno.2000.5902","article-title":"Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer","volume":"79","author":"Markman","year":"2000","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2003.08.001_BIB19","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1006\/gyno.2000.5921","article-title":"Phase 2 trial of liposomal doxorubicin (40 mg\/m2) in platinum\/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum","volume":"78","author":"Markman","year":"2000","journal-title":"Gynecol Oncol"},{"issue":"suppl 3","key":"10.1016\/j.ygyno.2003.08.001_BIB20","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1634\/theoncologist.6-suppl_3-26","article-title":"Weekly docetaxel in breast cancer","volume":"6","author":"Baselga","year":"2001","journal-title":"The Oncologist"},{"key":"10.1016\/j.ygyno.2003.08.001_BIB21","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1002\/1097-0142(20011015)92:8<2158::AID-CNCR1558>3.0.CO;2-2","article-title":"Phase II trial of weekly docetaxel in second-line therapy for nonsmall cell lung carcinoma","volume":"92","author":"Lilenbaum","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2003.08.001_BIB22","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1200\/JCO.1998.16.6.2164","article-title":"Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer","volume":"16","author":"Hainsworth","year":"1998","journal-title":"J Clin Oncol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825803005687?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825803005687?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,19]],"date-time":"2019-02-19T14:58:07Z","timestamp":1550588287000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825803005687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,12]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003,12]]}},"alternative-id":["S0090825803005687"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2003.08.001","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2003,12]]}}}